Listing your business on NASDAQ: An evening hosted by Wilson Sonsini Goodrich & Rosati and Cambridge Innovation Capital
Throughout the evening we will discuss:
Michael Labriola and Megan Baier from Wilson Sonsini Goodrich & Rosati (WSGR)
Silicon Valley-headquartered Wilson Sonsini works with more technology and life sciences companies on their IPOs, M&A transactions and venture financings than any other law firm globally. Wilson’s London office supports UK startups and scaleups through their US life cycle – US launch, expansion, fundraising, partnerships, M&A and IPO – and facilitates access to its transatlantic network of capital providers, corporates, and advisors.
Kevin Lee, Chief Executive Officer, Bicycle Therapeutics
Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and prior to that he lectured at Warwick University Medical School and founded Cambridge Biotechnology.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as “Bicycles®”, for diseases that are underserved by existing therapeutics. In May 2019, Bicycle completed its initial public offering (IPO) on the NASDAQ, with gross proceeds of $64.9 million.
Dr Michael Anstey is a Partner at CIC specialising in life science investments
Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan. Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease.
Michael manages CIC's investments in Bicycle Therapeutics, Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.
If you would like to attend, please email: firstname.lastname@example.org